406 related articles for article (PubMed ID: 17491584)
21. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
Van Cutsem E; Bajetta E; Valle J; Köhne CH; Hecht JR; Moore M; Germond C; Berg W; Chen BL; Jalava T; Lebwohl D; Meinhardt G; Laurent D; Lin E
J Clin Oncol; 2011 May; 29(15):2004-10. PubMed ID: 21464401
[TBL] [Abstract][Full Text] [Related]
22. [Systemic therapy for colorectal cancer].
Pestalozzi BC; Jäger D; Knuth A
Chirurg; 2005 Jun; 76(6):570-2, 574. PubMed ID: 15905968
[TBL] [Abstract][Full Text] [Related]
23. Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
Afonso S; Viani G; Afonso V; Stefano E; Afonso S
Anticancer Drugs; 2011 Jun; 22 Suppl 2():S21-3. PubMed ID: 21768794
[TBL] [Abstract][Full Text] [Related]
24. Oxaliplatin in the treatment of colorectal cancer.
Kim GP; Erlichman C
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):281-94. PubMed ID: 17428157
[TBL] [Abstract][Full Text] [Related]
25. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Yoo PS; Lopez-Soler RI; Longo WE; Cha CH
Clin Colorectal Cancer; 2006 Sep; 6(3):202-7. PubMed ID: 17026789
[TBL] [Abstract][Full Text] [Related]
26. Unusual ischemic complication of bevacizumab treatment for metastatic colorectal carcinoma.
Ryan EM; Hanly A; Morrin MM; McNamara DA
J Clin Oncol; 2013 Oct; 31(30):e433-4. PubMed ID: 23775957
[No Abstract] [Full Text] [Related]
27. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Tabernero J; Van Cutsem E; Díaz-Rubio E; Cervantes A; Humblet Y; André T; Van Laethem JL; Soulié P; Casado E; Verslype C; Valera JS; Tortora G; Ciardiello F; Kisker O; de Gramont A
J Clin Oncol; 2007 Nov; 25(33):5225-32. PubMed ID: 18024868
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy-free intervals in patients with metastatic colorectal cancer: a tale of two cities?
Beretta GD; Scartozzi M; Tondulli L; Cascinu S
J Clin Oncol; 2010 Jun; 28(16):e268-9; author reply e270. PubMed ID: 20385975
[No Abstract] [Full Text] [Related]
30. Recurrent disease four years after surgery and adjuvant chemotherapy.
Pozzo C; Barone C
Cancer Treat Rev; 2008; 34 Suppl 2():S8-11. PubMed ID: 19101406
[TBL] [Abstract][Full Text] [Related]
31. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T
Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010
[No Abstract] [Full Text] [Related]
32. The future development of bevacizumab in colorectal cancer.
Díaz-Rubio E; Schmoll HJ
Oncology; 2005; 69 Suppl 3():34-45. PubMed ID: 16301834
[TBL] [Abstract][Full Text] [Related]
33. [Chemotherapy with bevacizumab (BV)+modified FOLFOX6 for unresectable colorectal cancer].
Matsumoto R; Kuroda T; Yamada H; Hasegawa K; Mamiya Y; Kon A
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2207-9. PubMed ID: 20037372
[TBL] [Abstract][Full Text] [Related]
34. [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
Otsuka S; Inagaki M; Nishie M; Hamano R; Tokunaga N; Takahashi K; Tsunemitsu Y; Miyoshi K; Iwakawa K; Takahashi M; Iwagak H
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2166-8. PubMed ID: 20037358
[TBL] [Abstract][Full Text] [Related]
35. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.
Ducreux M; Ychou M; Laplanche A; Gamelin E; Lasser P; Husseini F; Quenet F; Viret F; Jacob JH; Boige V; Elias D; Delperro JR; Luboinski M;
J Clin Oncol; 2005 Aug; 23(22):4881-7. PubMed ID: 16009952
[TBL] [Abstract][Full Text] [Related]
36. Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency.
Sugimoto M; Yasuda H; Koda K; Yamazaki M; Tezuka T; Takenoue T; Kosugi C; Higuchi R; Yamamoto S; Watayo Y; Yagawa Y; Suzuki M
Hepatogastroenterology; 2007 Sep; 54(78):1684-8. PubMed ID: 18019695
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.
Baba K; Oshita A; Kohyama M; Inoue S; Kuroo Y; Yamaguchi T; Nakamura H; Sugiyama Y; Tazaki T; Sasaki M; Imamura Y; Daimaru Y; Ohdan H; Nakamitsu A
World J Gastroenterol; 2015 Feb; 21(6):1982-8. PubMed ID: 25684967
[TBL] [Abstract][Full Text] [Related]
38. Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases.
Neyns B; Aerts M; Van Nieuwenhove Y; Fontaine C; De Coster L; Schallier D; Vanderauwera J; De Munck F; Vandenbroucke F; Everaert H; Meert V; De Mey J; De Ridder M; Delvaux G; De Grève J
Anticancer Res; 2008; 28(4C):2459-67. PubMed ID: 18751435
[TBL] [Abstract][Full Text] [Related]
39. Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX.
Mori Y; Nishimura T; Kitano T; Yoshimura K; Matsumoto S; Kanai M; Hazama M; Ishiguro H; Nagayama S; Yanagihara K; Teramukai S; Chiba T; Sakai Y; Fukushima M
Oncology; 2010; 79(1-2):136-43. PubMed ID: 21150228
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]